BBIX.F Stock Overview
A clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Bonus BioGroup Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.02 |
| 52 Week High | ₪0.055 |
| 52 Week Low | ₪0.0003 |
| Beta | 1.04 |
| 11 Month Change | -20.00% |
| 3 Month Change | n/a |
| 1 Year Change | -33.33% |
| 33 Year Change | -96.23% |
| 5 Year Change | n/a |
| Change since IPO | -84.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| BBIX.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -10.5% | -2.1% |
| 1Y | -33.3% | 12.7% | 29.7% |
Return vs Industry: BBIX.F underperformed the US Biotechs industry which returned 12.7% over the past year.
Return vs Market: BBIX.F underperformed the US Market which returned 29.7% over the past year.
Price Volatility
| BBIX.F volatility | |
|---|---|
| BBIX.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BBIX.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine BBIX.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 58 | Shai Meretzki | bonus-bio.com |
Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company’s products in development include BonoFill for bone tissue regeneration in maxillofacial and orthopedic indications and is in Phase II clinical trial; and MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS and is in phase III trial. Its products in pipeline also comprise BonoFill for bone augmentation in osteoporosis patients; MesenCure for treating other inflammations and tissue damage; vascularized bone grafts; and soft tissue grafts.
Bonus BioGroup Ltd. Fundamentals Summary
| BBIX.F fundamental statistics | |
|---|---|
| Market cap | US$36.93m |
| Earnings (TTM) | -US$7.82m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.7x
P/E RatioIs BBIX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BBIX.F income statement (TTM) | |
|---|---|
| Revenue | ₪0 |
| Cost of Revenue | ₪0 |
| Gross Profit | ₪0 |
| Other Expenses | ₪29.19m |
| Earnings | -₪29.19m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.025 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BBIX.F perform over the long term?
See historical performance and comparison